Estados financieros detallados de Onconetix, Inc. (ONCO): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 80.4%, margen operativo -12.7%, margen neto -15.8%.
Al precio actual de $0.66, ONCO presenta beneficios negativos (P/E no significativo) y un ROE del -91.95%. La capitalización bursátil es de $2M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | $58465 | $2.5M | $815371 |
| Coste de Ventas | $573 | $3056 | $4890 | $6752 | $1.2M | $1.5M | $182458 |
| Beneficio Bruto | -$573 | -$3056 | -$4890 | -$6752 | -$1.1M | $1.1M | $632913 |
| I+D | $60174 | $524908 | $1.3M | $4.1M | $1.9M | $154359 | -$66133 |
| Generales y Administrativos | $819485 | $1.1M | $2.1M | $9.4M | $14.8M | $11.2M | $7.0M |
| Gastos Operativos | $879659 | $1.6M | $3.4M | $13.5M | $34.9M | $57.5M | $7.0M |
| Beneficio Operativo | -$880230 | -$1.6M | -$3.4M | -$13.5M | -$36.0M | -$56.5M | -$6.3M |
| EBITDA | -$821342 | -$1.6M | -$3.4M | -$13.4M | -$36.7M | -$57.6M | -$13.3M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | $671625 | $1.4M | $751005 |
| Beneficio Antes de Impuestos | -$821915 | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$59.7M | -$14.0M |
| Impuestos | 0 | 0 | 0 | 0 | -$12593 | -$1.0M | $525 |
| Beneficio Neto | -$821915 | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| BPA | $-0.02 | $-0.04 | $-0.09 | $-0.31 | $-25.03 | $-520.93 | $-4.73 |
| BPA Diluido | $-0.02 | $-0.04 | $-0.09 | $-0.31 | $-25.03 | $-520.93 | $-4.73 |
| Acciones en Circulación (Diluidas) | $11372 | $11372 | $11372 | $12632 | $17612 | $113050 | $3.3M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $6.1M | $4.3M | $1.9M | $25.8M | $4.6M | $646500 | $5.2M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $8330 | $44805 | $152524 | $35850 | $149731 | $96308 | $296866 |
| Inventario | 0 | 0 | 0 | 0 | $364052 | $64079 | $149961 |
| Activos Corrientes | $6.1M | $4.6M | $3.1M | $26.3M | $5.8M | $950267 | $6.1M |
| Inmovilizado Material | $6931 | $15667 | $11502 | $14089 | $209196 | $182323 | $85859 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | $55.7M | $27.0M | $18.5M |
| Activos Intangibles | 0 | 0 | 0 | 0 | $25.4M | 0 | 0 |
| Activos Totales | $6.1M | $4.8M | $3.1M | $26.3M | $87.5M | $28.2M | $24.9M |
| Cuentas por Pagar | $18377 | $68668 | $582605 | $1.5M | $5.3M | $3.8M | $1.8M |
| Deuda a Corto | 0 | 0 | 0 | 0 | $9.6M | $9.3M | 0 |
| Pasivos Corrientes | $75762 | $68668 | $1.6M | $3.9M | $17.2M | $18.3M | $9.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | $118857 | 0 | $24362 |
| Pasivos Totales | $82621 | $78310 | $1.6M | $3.9M | $86.1M | $18.6M | $9.2M |
| Reservas | -$939870 | -$2.5M | -$6.0M | -$19.4M | -$56.8M | -$115.7M | -$131.2M |
| Patrimonio Neto | $6.0M | $4.7M | $1.4M | $22.4M | -$5.6M | $9.6M | $15.8M |
| Deuda Total | 0 | 0 | 0 | 0 | $9.9M | $9.4M | $48774 |
| Deuda Neta | -$6.1M | -$4.3M | -$1.9M | -$25.8M | $5.3M | $8.8M | -$5.2M |
| Capital Circulante | $6.0M | $4.5M | $1.4M | $22.3M | -$11.4M | -$17.3M | -$3.1M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$821915 | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| Amortizaciones | $573 | $3056 | $4890 | $6752 | $43937 | $731345 | $15170 |
| Compensación en Acciones | $3266 | $334837 | $130141 | $2.0M | $329760 | $438653 | $74267 |
| Cambio en Capital Circulante | -$7050 | -$468565 | $1.2M | $2.6M | $1.6M | -$1.5M | -$2.4M |
| Flujo de Caja Operativo | -$825126 | -$1.7M | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
| Inversiones (CapEx) | -$4500 | -$11792 | -$1924 | -$9339 | -$55044 | -$28471 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | -$566810 | -$58981 | -$718 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | -$206404 | 0 |
| Flujo de Caja Libre | -$829626 | -$1.7M | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +4217.3% | -67.7% | |||||
| Crecimiento Beneficio Neto (anual) | -94.6% | -113.7% | -292.7% | -178.8% | -56.9% | +76.1% | |
| Crecimiento BPA (anual) | -88.2% | -121.4% | -251.6% | -7936.7% | -1981.3% | +99.1% | |
| Cambio en Acciones (anual) | +0.0% | +0.0% | +11.1% | +39.4% | +541.9% | +2803.1% | |
| Crecimiento FCF (anual) | -110.0% | -17.5% | -324.4% | -57.0% | +22.8% | +8.0% | |
| Margen Bruto | -1927.9% | 41.8% | 77.6% | ||||
| Margen Operativo | -61634.5% | -2238.0% | -778.2% | ||||
| Margen EBITDA | -62784.1% | -2281.9% | -1626.9% | ||||
| Margen Neto | -63986.5% | -2325.2% | -1721.0% | ||||
| Margen FCF | -23323.5% | -416.9% | -1187.0% | ||||
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% | 1.7% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-72.96 | $-153.18 | $-179.94 | $-687.56 | $-774.25 | $-93.09 | $-2.95 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.83 | $0.00 |
| Acciones en Circulación (Básicas) | $11372 | $11372 | $11372 | $12632 | $17612 | $113050 | $3.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -91.95% |
| Rentabilidad sobre capital invertido | -59.84% |
| Rentabilidad sobre activos | -62.07% |
| Margen bruto | 80.40% |
| Margen operativo | -1265.55% |
| Margen neto | -1578.79% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 2.21 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -459045698.92 | -243950000.00 | -110170967.74 | -600458.72 | -1344.86 | -5.14 | -16.49 |
| P/VC | 18498.79 | 23440.75 | 76707.36 | 105.51 | -105.82 | 31.50 | 16.24 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 10139.74 | 119.92 | 313.95 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | -1927.9% | 41.8% | 77.6% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -61634.5% | -2238.0% | -778.2% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -63986.5% | -2325.2% | -1721.0% |
Empresas relacionadas: AZTR · ENVB · INDP · JSPR · PTIX · REVB · SCNI
Explorar sector: Healthcare · Biotechnology
Más secciones de ONCO: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones